On February 27, 2026, TransMedics Group, Inc. announced impacts related to the release of its U.S. valuation allowance on deferred tax assets, affecting its previously reported financial results for the quarter ended December 31, 2025. This filing is significant for investors as it relates to financial performance, and carries a neutral sentiment.